Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTD2 Combined With Doxorubicin and Tislelizumab for Advanced Soft Tissue Sarcoma
NCT07842276Phase 2Not yet recruiting
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Start
- Oct 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 2 trial of utidelone in soft tissue sarcoma (STS), sponsored by Beijing Biostar Pharmaceuticals Co., Ltd.. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
utidelone
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT07842276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07842276.